About Transition Therapeutics (NASDAQ:TTHI)
Transition Therapeutics Inc. is a product-focused biopharmaceutical company. The Company's principal business activity is the researching and developing of therapeutic agents. The Company is developing therapeutics for central nervous system (CNS) and metabolic disease indications. The Company's technologies are focused on the treatment of agitation and aggression in Alzheimer's disease and diabetes. The Company's subsidiary, Transition Therapeutics Ireland Limited (Transition Ireland), is developing two drug candidates: neuropsychiatric candidate ELND005 and androgen deficiency candidate TT701. The Company's subsidiary, Waratah Pharmaceuticals Inc. (Waratah), is developing diabetes drug candidate TT401. The Company's other two entities provide development services in support of the clinical and non-clinical activities of Transition Ireland and Waratah.
Industry, Sector and Symbol:
- Sector: Medical
- Industry: Biotechnology
- Sub-Industry: N/A
- Symbol: NASDAQ:TTHI
- CUSIP: N/A
- Web: N/A
- 50 Day Moving Avg: $1.59
- 200 Day Moving Avg: $1.11
- 52 Week Range: $0.66 - $2.75
- Trailing P/E Ratio: N/A
- Foreward P/E Ratio: -2.67
- P/E Growth: 0.00
- Average Volume: 86,277 shs.
- Beta: 1.59
Frequently Asked Questions for Transition Therapeutics (NASDAQ:TTHI)
What is Transition Therapeutics' stock symbol?
Transition Therapeutics trades on the NASDAQ under the ticker symbol "TTHI."
How were Transition Therapeutics' earnings last quarter?
Transition Therapeutics Inc (NASDAQ:TTHI) posted its quarterly earnings data on Tuesday, September, 15th. The company reported ($0.31) EPS for the quarter, beating the Thomson Reuters' consensus estimate of ($0.39) by $0.08. View Transition Therapeutics' Earnings History.
Who are some of Transition Therapeutics' key competitors?
Some companies that are related to Transition Therapeutics include Amgen (AMGN), Celgene (CELG), Gilead Sciences (GILD), Biogen (BIIB), Regeneron Pharmaceuticals (REGN), Vertex Pharmaceuticals Incorporated (VRTX), Grifols SA, Barcelona (GRFS), Incyte (INCY), Alexion Pharmaceuticals (ALXN), Illumina (ILMN), BioMarin Pharmaceutical (BMRN), Seattle Genetics (SGEN), Jazz Pharmaceuticals plc - (JAZZ), TESARO (TSRO), Alnylam Pharmaceuticals (ALNY), Exelixis (EXEL), BIO-TECHNE Corp (TECH) and Kite Pharma (KITE).
How do I buy Transition Therapeutics stock?
Shares of Transition Therapeutics can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
How much does a share of Transition Therapeutics stock cost?
One share of Transition Therapeutics stock can currently be purchased for approximately $1.52.
Consensus Ratings for Transition Therapeutics (NASDAQ:TTHI) (?) The ratings breakdown includes the most recent rating from each analyst that has rated the stock within the last twelve months. The ratings score is a calculation of the average number of sell, hold, buy and strong buy ratings (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). The consensus price target is a mean average of the most recent price target set by each analyst that has set a price target for the stock in the last twelve months.
|Ratings Breakdown: ||No ratings tracked in the last 12 months.|
|Consensus Rating:||N/A (Score: NaN)|
|Consensus Price Target: ||N/A|
Analysts' Ratings History for Transition Therapeutics (NASDAQ:TTHI)
(Data available from 5/23/2015 forward)
|Date||Firm||Action||Rating||Price Target||Impact on Share Price||Details|
|5/14/2016||Cowen and Company||Reiterated Rating||Hold||N/A|
|4/19/2016||Canaccord Genuity||Reiterated Rating||Hold||N/A|
Earnings History for Transition Therapeutics (NASDAQ:TTHI)Earnings History by Quarter for Transition Therapeutics (NASDAQ:TTHI)
(Data available from 1/1/2011 forward)
|Date||Quarter||Consensus Estimate||Actual EPS||Revenue Estimate||Actual Revenue||Release Link||Conference Call||Details|
Earnings Estimates for Transition Therapeutics (NASDAQ:TTHI)
Current Year EPS Consensus Estimate: $-0.33 EPS
Next Year EPS Consensus Estimate: $-0.57 EPS
Dividend History for Transition Therapeutics (NASDAQ:TTHI)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading History for Transition Therapeutics (NASDAQ:TTHI)
No insider trades for this company have been tracked by MarketBeat.com
Headline Trends for Transition Therapeutics (NASDAQ:TTHI)
Latest Headlines for Transition Therapeutics (NASDAQ:TTHI)
Transition Therapeutics (TTHI) Chart for Tuesday, May, 23, 2017